Evidence map›Paper›PMID 27317411›Full record

ArticleAIDS and behavior2017

Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.

K Rivet Amico, Melissa Wallace, Linda-Gail Bekker, Surita Roux, Millicent Atujuna, Elaine Sebastian, Bonnie J Dye, Vanessa Elharrar, Robert M Grant

Open access · hybridAbstract read
In one paragraph

Article in AIDS and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

K Rivet AmicoDepartment of Health Behavior and Health Education, University of Michigan, Ann Arbor, MI, USA. ramico@umich.edu.
Melissa WallaceThe Desmond Tutu HIV Centre, Cape Town, South Africa.
Linda-Gail BekkerDept of Medicine and Institute of Infectious Disease and Molecular Medicine, The Desmond Tutu HIV Centre, Cape Town, South Africa.
Surita RouxThe Desmond Tutu HIV Centre, Cape Town, South Africa.
Millicent AtujunaThe Desmond Tutu HIV Centre, Cape Town, South Africa.
Elaine SebastianThe Desmond Tutu HIV Centre, Cape Town, South Africa.
Bonnie J DyeFHI 360, Durham, NC, USA.
Vanessa ElharrarClinical Prevention Research Branch, PSP/DAIDS/NIAID/NIH, Bethesda, MD, USA.
Robert M GrantGladstone Institutes, San Francisco AIDS Foundation, University of California, San Francisco, CA, USA.
Desmond Tutu HIV Foundation · ZAFamily Health International 360 · USUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · US

Funding

Chemoprophylaxis and HIV Host InteractionsR01AI118575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANT, ROBERT M. · 2015 to 2019
$2.9M
NIAID NIH HHS R01 AI118575
6 · The paper itself

Abstract

Placebo-controlled trials of pre-exposure prophylaxis (PrEP) have reported challenges with study-product uptake and use, with the greatest challenges reported in studies with young women in sub-Saharan Africa. We conducted a qualitative sub-study to explore experiences with open-label PrEP among young women in Cape Town, South Africa participating in HTPN 067/Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking (ADAPT). HPTN 067/ADAPT provided open label oral FTC/TDF PrEP to young women in Cape Town, South Africa who were randomized to daily and non-daily PrEP regimens. Following completion of study participation, women were invited into a qualitative sub-study including focus groups and in-depth interviews. Interviews and groups followed a semi-structured guide, were recorded, transcribed, and translated to English from isiXhosa, and coded using framework analysis. Sixty of the 179 women enrolled in HPTN 067/ADAPT participated in either a focus group (six groups for a total of 42 participants) or an in-depth interview (n = 18). This sample of mostly young, unmarried women identified facilitators of and barriers to PrEP use, as well as factors influencing study participation. Cross-cutting themes characterizing discourse suggested that women placed high value on contributing to the well-being of one's community (Ubuntu), experienced a degree of skepticism towards PrEP and the study more generally, and reported a wide range of approaches towards PrEP (ranging from active avoidance to high levels of persistence and adherence). A Mutuality Framework is proposed that identifies four dynamics (distrust, uncertainty, alignment, and mutuality) that represent distinct interactions between self, community and study and serve to contextualize women's experiences. Implications for better understanding PrEP use, and non-use, and intervention opportunities are discussed. In this sample of women, PrEP use in the context of an open-label research trial was heavily influenced by underlying beliefs about safety, reciprocity of contributions to community, and trust in transparency and integrity of the research. Greater attention to factors positioning women in the different dynamics of the proposed Mutuality Framework could direct intervention approaches in clinical trials, as well as open-label PrEP scale-up.

Indexed as

Medication AdherenceSocial StigmaAdultAnti-HIV AgentsFemaleFocus GroupsHIV InfectionsHumansInterviews as TopicPatient Acceptance of Health CarePre-Exposure ProphylaxisProgram EvaluationQualitative ResearchSouth AfricaYoung AdultAnti-HIV AgentsAdherenceBarriersMutuality frameworkOpen-labelPrEPSouth AfricaWomen

Identifiers

PMID27317411
PMCPMC5378745
OpenAlexW2423803673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.